- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01083888
ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis
January 6, 2020 updated by: Astellas Pharma Inc
ASP1517 Clinical Pharmacological Study Examination of Pharmacokinetics and Pharmacodynamics in Patients With Renal Anemia Undergoing Hemodialysis
To assess the Pharmacokinetics and pharmacodynamics of single doses of ASP1517 in renal anemia patients on hemodialysis.
Safety and tolerability will be also evaluated in these patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 74 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic renal failure patients receiving hemodialysis thrice weekly
- Body weight: >=40.0 and <80.0 kg
- Mean hemoglobin level >=10.0 and =<12.0 g/dL
Exclusion Criteria:
- Patients with severe inflammation or infection
- Patients who have a medical history of gastrointestinal surgery or enterectomy
- Patients who have uncontrolled hypertension
- Patients whose AST, ALT, total bilirubin, GGT exceed the ULN or those who have a medical history of serious liver diseases
- Patients who have a medical history of severe cardiac or cerebrovascular diseases
- Patients who have received blood transfusion or who have had a surgery (except surgery for a shunt) within 4 weeks
- Patients with a medical history of serious drug allergies
- Patients who may be pregnant or lactating, or who refuse to use required birth control during the study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1 group
Participants received a single oral dose of ASP1517 on Days 1 and 8
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ASP1517 concentrations in plasma
Time Frame: For 96 hours after dosing
|
For 96 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ASP1517 concentrations in dialysate
Time Frame: For 6 hours after dosing
|
For 6 hours after dosing
|
Plasma EPO level
Time Frame: Pre dosing and for 24 hours after dosing
|
Pre dosing and for 24 hours after dosing
|
Safety assessed by Adverse Event, vital signs standard 12-lead ECG or lab tests
Time Frame: For 96 hours after dosing
|
For 96 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 15, 2010
Primary Completion (ACTUAL)
June 7, 2010
Study Completion (ACTUAL)
June 7, 2010
Study Registration Dates
First Submitted
March 8, 2010
First Submitted That Met QC Criteria
March 8, 2010
First Posted (ESTIMATE)
March 10, 2010
Study Record Updates
Last Update Posted (ACTUAL)
January 9, 2020
Last Update Submitted That Met QC Criteria
January 6, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1517-CL-0203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on roxadustat
-
Astellas Pharma IncFibroGenCompletedChronic Kidney DiseaseJapan
-
Astellas Pharma IncFibroGenCompletedESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Sunshine Lake Pharma Co., Ltd.Nicoya Therapeutics (Shanghai) Co., Ltd.Not yet recruitingChronic Kidney Diseases | Renal AnemiaChina
-
FibroGenAstraZenecaWithdrawnAnemia Associated With Chronic Kidney DiseaseUnited States
-
FibroGenAstraZeneca; Astellas Pharma IncCompletedChemotherapy Induced AnemiaUnited States
-
Mao JianhuaRecruitingAnemia Associated With Chronic Kidney DiseaseChina
-
Astellas Pharma Europe B.V.FibroGenCompletedImpaired Renal Function | Normal Renal FunctionGermany, United Kingdom
-
Astellas Pharma Global Development, Inc.FibroGenCompletedHealthy Adult SubjectsGermany
-
Ruijin HospitalRecruitingST Elevation Myocardial InfarctionChina